TAGLN3

Summary

TAGLN3 (transgelin 3, HGNC:29868) is a protein-coding gene on chromosome 3q13.2, encoding Transgelin-3 (Q9UI15).

Predicted to enable actin filament binding activity. Predicted to be involved in actin filament organization. Predicted to act upstream of or within negative regulation of transcription by RNA polymerase II. Predicted to be located in nucleus. Predicted to be active in actin cytoskeleton and synapse.

Source: NCBI Gene 29114 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 23 total
• MANE Select transcript: NM_001008272

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29868
Approved symbol	TAGLN3
Name	transgelin 3
Location	3q13.2
Locus type	gene with protein product
Status	Approved
Aliases	NP25, NP22
Ensembl gene	ENSG00000144834
Ensembl biotype	protein_coding
OMIM	607953
Entrez	29114

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 13 protein_coding

ENST00000273368, ENST00000393917, ENST00000455401, ENST00000469385, ENST00000478951, ENST00000486460, ENST00000494932, ENST00000900319, ENST00000900320, ENST00000900321, ENST00000941320, ENST00000941321, ENST00000941322

RefSeq mRNA: 3 — MANE Select: NM_001008272 NM_001008272, NM_001008273, NM_013259

CCDS: CCDS33816

Canonical transcript exons

ENST00000478951 — 5 exons

Exon	Start	End
ENSE00000967413	112011763	112011865
ENSE00001200287	111999421	111999602
ENSE00001842377	111998922	111999114
ENSE00001934245	112013410	112013885
ENSE00003608560	112000772	112000946

Expression profiles

Bgee: expression breadth ubiquitous, 194 present calls, max score 99.34.

FANTOM5 (CAGE): breadth broad, TPM avg 13.6937 / max 394.4322, expressed in 520 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
37913	5.7358	483
37908	4.9251	265
37912	1.3685	266
37914	0.4387	125
37906	0.3597	98
37911	0.2996	140
37909	0.1863	119
37910	0.1626	105
37905	0.1326	67
37904	0.0847	51

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
frontal pole	UBERON:0002795	99.34	gold quality
right frontal lobe	UBERON:0002810	99.29	gold quality
Brodmann (1909) area 10	UBERON:0013541	99.29	gold quality
prefrontal cortex	UBERON:0000451	99.28	gold quality
cerebellar cortex	UBERON:0002129	99.15	gold quality
cerebellar hemisphere	UBERON:0002245	99.15	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	99.12	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.12	gold quality
Brodmann (1909) area 9	UBERON:0013540	99.09	gold quality
frontal cortex	UBERON:0001870	99.07	gold quality
frontal lobe	UBERON:0016525	99.07	gold quality
cerebellum	UBERON:0002037	98.99	gold quality
ganglionic eminence	UBERON:0004023	98.99	gold quality
cingulate cortex	UBERON:0003027	98.97	gold quality
anterior cingulate cortex	UBERON:0009835	98.96	gold quality
neocortex	UBERON:0001950	98.90	gold quality
pons	UBERON:0000988	98.88	gold quality
cortical plate	UBERON:0005343	98.77	gold quality
nucleus accumbens	UBERON:0001882	98.73	gold quality
amygdala	UBERON:0001876	98.68	gold quality
cerebral cortex	UBERON:0000956	98.47	gold quality
superior frontal gyrus	UBERON:0002661	98.35	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.17	gold quality
caudate nucleus	UBERON:0001873	98.16	gold quality
telencephalon	UBERON:0001893	98.14	gold quality
cerebellar vermis	UBERON:0004720	98.10	gold quality
hypothalamus	UBERON:0001898	98.07	gold quality
orbitofrontal cortex	UBERON:0004167	98.06	gold quality
putamen	UBERON:0001874	98.03	gold quality
paraflocculus	UBERON:0005351	98.00	gold quality

Single-cell (SCXA)

Detected in 14 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-MTAB-6911	yes	2482.61
E-HCAD-56	yes	2274.56
E-MTAB-7316	yes	1587.94
E-MTAB-10485	yes	1433.93
E-HCAD-5	yes	672.07
E-GEOD-93593	yes	667.83
E-MTAB-6108	yes	516.38
E-MTAB-5061	yes	14.83
E-CURD-114	yes	11.67
E-GEOD-83139	yes	8.43
E-GEOD-84465	yes	7.38
E-GEOD-137537	yes	5.34
E-HCAD-10	yes	5.07
E-ANND-3	no	3.31

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

29 targeting TAGLN3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-4470	99.66	69.35	1767
HSA-MIR-190B-3P	99.33	68.29	1382
HSA-MIR-5584-3P	99.23	68.79	1351
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-3168	99.08	67.75	1384
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-153-3P	98.96	72.51	1644
HSA-MIR-138-2-3P	98.91	68.33	1643
HSA-MIR-4709-3P	98.88	68.04	1594
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-4723-3P	97.67	65.91	1017
HSA-MIR-495-5P	97.62	68.28	682
HSA-MIR-6831-3P	97.49	69.29	505
HSA-MIR-6769B-3P	97.41	65.53	1036
HSA-MIR-3183	97.40	65.68	978
HSA-MIR-148B-5P	97.29	66.30	992
HSA-MIR-6874-3P	97.29	66.34	975
HSA-MIR-382-5P	96.71	65.90	762
HSA-MIR-6815-5P	96.05	65.55	662
HSA-MIR-6865-5P	96.05	65.58	675
HSA-MIR-6753-5P	94.70	64.08	470
HSA-MIR-1307-3P	66.08	59.35	14

Literature-anchored findings (GeneRIF, showing 2)

• Western blots revealed a significant increase in hNP22 protein levels in the frontal cortex but not the motor cortex of alcoholic cases. (PMID:14506410)
• Altered expression of hNP22 may be associated with modifications in neuronal cytoarchitecture leading to dysregulation of neural signal transduction in the anterior cingulate cortex of the schizophrenia brain. (PMID:15781144)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	tagln3a	ENSDARG00000079805
mus_musculus	Tagln3	ENSMUSG00000022658
rattus_norvegicus	Tagln3	ENSRNOG00000064186
drosophila_melanogaster	Mp20	FBGN0002789
drosophila_melanogaster	Chd64	FBGN0035499
caenorhabditis_elegans	cpn-1	WBGENE00000777
caenorhabditis_elegans		WBGENE00000778
caenorhabditis_elegans	cpn-3	WBGENE00000779
caenorhabditis_elegans	cpn-4	WBGENE00000780

Paralogs (5): CNN2 (ENSG00000064666), CNN3 (ENSG00000117519), CNN1 (ENSG00000130176), TAGLN (ENSG00000149591), TAGLN2 (ENSG00000158710)

Protein

Protein identifiers

Transgelin-3 — Q9UI15 (reviewed: Q9UI15)

Alternative names: Neuronal protein 22, Neuronal protein NP25

All UniProt accessions (4): Q9UI15, C9J5W6, C9JCX3, H7C5N2

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Widely expressed in the brain. Expression is increased in the superior frontal cortex of alcoholics, but not in the motor cortex or cerebellum.

Similarity. Belongs to the calponin family.

RefSeq proteins (3): NP_001008273, NP_001008274, NP_037391 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000557	Calponin_repeat	Repeat
IPR001715	CH_dom	Domain
IPR003096	SM22_calponin	Family
IPR036872	CH_dom_sf	Homologous_superfamily
IPR050606	Calponin-like	Family

Pfam: PF00307, PF00402

UniProt features (6 total): chain 1, domain 1, repeat 1, region of interest 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UI15-F1	87.97	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 163

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 136 (showing top): ENK_UV_RESPONSE_KERATINOCYTE_UP, CTATGCA_MIR153, MODULE_503, MODULE_66, MODULE_195, MODULE_379, GOBP_ACTIN_FILAMENT_ORGANIZATION, GNF2_TM4SF2, SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_DN, DAZARD_RESPONSE_TO_UV_SCC_UP, MODULE_147, GOMF_ACTIN_BINDING, CREBP1_01, MODULE_242, GNF2_RAB3A

GO Biological Process (3): negative regulation of transcription by RNA polymerase II (GO:0000122), actin filament organization (GO:0007015), central nervous system development (GO:0007417)

GO Molecular Function (2): actin filament binding (GO:0051015), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), actin cytoskeleton (GO:0015629), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
actin cytoskeleton organization	1
supramolecular fiber organization	1
nervous system development	1
system development	1
actin binding	1
protein-containing complex binding	1
binding	1
intracellular membrane-bounded organelle	1
cytoskeleton	1
cell junction	1

Protein interactions and networks

STRING

3958 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TAGLN3	LIM2	P55344	768
TAGLN3	CALD1	Q05682	659
TAGLN3	MYH11	P35749	604
TAGLN3	CFL1	P23528	601
TAGLN3	SCIN	Q9Y6U3	560
TAGLN3	GSN	P06396	560
TAGLN3	FCGR2B	P31994	559
TAGLN3	TPM1	P09493	557
TAGLN3	SMTN	P53814	544
TAGLN3	FCGR2A	P12318	543
TAGLN3	MYL9	P24844	530
TAGLN3	ACTA2	P03996	520
TAGLN3	FLNB	O75369	499
TAGLN3	FLNC	Q14315	495
TAGLN3	COMP	P49747	493

IntAct

15 interactions, top by confidence:

A	B	Type	Score
TAGLN2	TAGLN3	psi-mi:“MI:0915”(physical association)	0.640
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
TAGLN2	VSIG8	psi-mi:“MI:0914”(association)	0.350
VCP	SHTN1	psi-mi:“MI:0914”(association)	0.350
VCP	FAM171A2	psi-mi:“MI:0914”(association)	0.350
MAPT	PITPNM1	psi-mi:“MI:2364”(proximity)	0.270
MAPT	DCTN6	psi-mi:“MI:2364”(proximity)	0.270
MAPT		psi-mi:“MI:2364”(proximity)	0.270

BioGRID (43): CLIC1 (Co-fractionation), CLIC4 (Co-fractionation), DUT (Co-fractionation), ENO1 (Co-fractionation), ENO2 (Co-fractionation), ENO3 (Co-fractionation), FABP5 (Co-fractionation), FABP7 (Co-fractionation), FKBP1A (Co-fractionation), FKBP1B (Co-fractionation), HSPE1 (Co-fractionation), NUTF2 (Co-fractionation), PGK2 (Co-fractionation), PIN1 (Co-fractionation), SNX12 (Co-fractionation)

ESM2 similar proteins: A6H742, A7E3Q8, O13728, O14134, O14185, O59945, O88818, P05095, P13796, P13797, P19179, P19966, P32599, P37803, P37804, P37805, P41810, P53585, P53978, P54680, P78820, P87078, Q00955, Q01995, Q08873, Q14651, Q3V0K9, Q3ZBY2, Q4R5J4, Q54BC6, Q54HG2, Q550R2, Q55BP5, Q5R6R2, Q61233, Q63598, Q6DG81, Q6FIR8, Q6FM46, Q6P698

Diamond homologs: O14185, P14318, P37805, Q08873, Q24799, Q3ZBY2, Q4R5J4, Q55E26, Q5R6R2, Q9R1Q8, Q9UI15, B9EUM5, O14188, P19966, P26932, P31232, P37397, P37802, P37803, P37804, P46940, P51911, Q01995, Q08091, Q08092, Q08093, Q08094, Q08290, Q12280, Q15052, Q15417, Q2HJ38, Q32L92, Q3SYU6, Q54TK8, Q55GV9, Q5AH02, Q5E9F5, Q5RFN6, Q5XFX0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

23 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

718 predictions. Top by Δscore:

Variant	Effect	Δscore
3:111999598:GGACG:G	donor_gain	1.0000
3:111999599:GACGG:G	donor_gain	1.0000
3:112000767:TTCA:T	acceptor_loss	1.0000
3:112000768:TCA:T	acceptor_loss	1.0000
3:112000769:CA:C	acceptor_loss	1.0000
3:112000770:A:AG	acceptor_gain	1.0000
3:112000770:A:AT	acceptor_loss	1.0000
3:112000771:G:GG	acceptor_gain	1.0000
3:112000943:G:GT	donor_gain	1.0000
3:112000943:G:T	donor_gain	1.0000
3:112000943:GAAGG:G	donor_loss	1.0000
3:112000944:A:T	donor_gain	1.0000
3:112000944:AAG:A	donor_loss	1.0000
3:112000945:AGGTA:A	donor_loss	1.0000
3:112000946:GGTA:G	donor_loss	1.0000
3:112000947:G:GC	donor_loss	1.0000
3:112000948:T:G	donor_loss	1.0000
3:111998786:G:T	donor_gain	0.9900
3:111998787:A:T	donor_gain	0.9900
3:111998801:A:G	donor_gain	0.9900
3:111998981:G:GT	donor_gain	0.9900
3:111999062:G:T	donor_gain	0.9900
3:111999111:GATT:G	donor_gain	0.9900
3:111999115:G:GG	donor_gain	0.9900
3:111999543:G:GT	donor_gain	0.9900
3:111999599:GACG:G	donor_gain	0.9900
3:111999600:ACGG:A	donor_loss	0.9900
3:111999602:GGTA:G	donor_loss	0.9900
3:111999603:G:GA	donor_loss	0.9900
3:111999603:G:GG	donor_gain	0.9900

AlphaMissense

1318 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:112000850:T:C	F87L	1.000
3:112000852:T:A	F87L	1.000
3:112000852:T:G	F87L	1.000
3:111999597:G:T	G59W	0.999
3:112000922:T:C	F111L	0.999
3:112000924:T:A	F111L	0.999
3:112000924:T:G	F111L	0.999
3:112013538:G:T	R196M	0.999
3:111999519:T:A	W33R	0.998
3:111999519:T:C	W33R	0.998
3:111999598:G:A	G59E	0.998
3:111999598:G:T	G59V	0.998
3:112000851:T:C	F87S	0.998
3:112000851:T:G	F87C	0.998
3:112000938:T:C	L116P	0.998
3:112013435:T:C	F162L	0.998
3:112013437:T:A	F162L	0.998
3:112013437:T:G	F162L	0.998
3:112013529:G:A	G193E	0.998
3:112013538:G:C	R196T	0.998
3:111999448:G:A	G9D	0.997
3:112000785:T:C	L65P	0.997
3:112000860:T:C	M90T	0.997
3:112000861:G:A	M90I	0.997
3:112000861:G:C	M90I	0.997
3:112000861:G:T	M90I	0.997
3:112000877:T:C	F96L	0.997
3:112000879:C:A	F96L	0.997
3:112000879:C:G	F96L	0.997
3:112000881:T:C	L97P	0.997

dbSNP variants (sampled 300 via entrez): RS1000053639 (3:112003400 A>G), RS1000691106 (3:112006047 C>A), RS1000708177 (3:112014304 A>G), RS1000806594 (3:112006309 T>G), RS1000855173 (3:112006780 A>C,G), RS1000937917 (3:112013948 T>C), RS1000984070 (3:112013000 G>A), RS1001148921 (3:112007027 C>A), RS1001261958 (3:112007242 C>A,T), RS1001268816 (3:112000760 C>G,T), RS1001342615 (3:111999568 G>A,C), RS1001494107 (3:112007079 T>C,G), RS1001813522 (3:112011065 C>CCTTGCATGGACTTTTGGT), RS1002137512 (3:112012311 T>C,G), RS1002994023 (3:112010744 G>C)

Disease associations

OMIM: gene MIM:607953 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	7
entinostat	decreases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
aristolochic acid I	increases expression	1
2,4,6-tribromophenol	decreases expression	1
bisphenol A	decreases expression	1
decabromobiphenyl ether	decreases expression	1
trichostatin A	decreases expression	1
arsenite	increases methylation	1
tetrabromobisphenol A	decreases expression	1
ochratoxin A	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, increases expression	1
phenethyl isothiocyanate	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	affects cotreatment, decreases methylation	1
LDN 193189	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Decitabine	affects expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Benzo(a)pyrene	decreases methylation	1
Boron Compounds	increases expression	1
Cisplatin	affects expression	1
Cocaine	decreases expression	1
Daunorubicin	affects response to substance	1
Diethylhexyl Phthalate	decreases expression	1
Ivermectin	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.